Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Sponsors
Tata Memorial Hospital
Eligibility
Inclusion criteria
Inclusion criteria: - Newly diagnosed, treatment-naive breast cancer patients - Histological or cytological confirmation of breast cancer diagnosis before or after coming to TMH, Parel. - Visiting the Breast DMG General or Private OPDs in TMH Parel during a 1 month period from the start of the study. - Undergoing standard diagnostic and staging workup as decided in the DMG - Adults of any age, sex or menopausal status - Any stage, histology or its subtype
Exclusion criteria
Exclusion criteria: - Has started any form of breast cancer treatment Recurrent breast cancer - Not willing to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To establish the prevalence and severity of serum 25-Hydroxyvitamin D deficiency in newly diagnosed breast cancer patientsTimepoint: Baseline at Diagnosis | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To establish the correlation between baseline serum 25-hydroxyvitamin D levels and : - Reported history of 25-Hydroxyvitamin D supplementation - Sun exposure - Fitzpatrick sun-reactive skin typing - Diet - BMI - Known comorbidities - Concomitant medication - VDR Polymorphism (not for this dissertation, but later on stored samples). 2. Physician s practice for Vit. D supplementation and monitoring in breast cancer patients 3. Correlation between serum Vit. D level at diagnosis with - Stage of breast cancer - Subtype of breast cancer - QoL as measured by TMQ at Baseline and at 1 year. - 2yr DFS.Timepoint: -Baseline -1yr -2yr | — |
Countries
India
Contacts
Public ContactRajiv Sarin
Tata Memorial Hospital
Outcome results
None listed